Sonnet BioTherapeutics, a Nasdaq-listed clinical-stage biotechnology firm, mentioned it would merge with Rorschach I LLC in an all-stock deal that values the mixed enterprise at about $888 million
Sonnet BioTherapeutics, a Nasdaq-listed clinical-stage biotechnology firm, mentioned it would merge with Rorschach I LLC in an all-stock deal that values the mixed enterprise at about $888 million.
The brand new entity, Hyperliquid Methods Inc., will pivot away from drug improvement to give attention to managing digital belongings tied to the Hyperliquid Layer-1 blockchain. It plans to carry 12.6 million HYPE tokens and roughly $305 million in money as a treasury reserve, based on a joint assertion issued Monday.
Rorschach I is backed by Atlas Service provider Capital and Paradigm Operations, buyers higher recognized for his or her publicity to financial-services and crypto ventures. Following the transaction, Sonnet shareholders will personal a minority stake in Hyperliquid Methods, whose administration mentioned it intends to hunt additional alternatives in on-chain liquidity provision and token-based monetary merchandise.
That is an AI-generated article powered by DeepNewz, curated by The Defiant. For extra info, together with article sources, go to DeepNewz.
